<p>Kenneth Kelley of PaxVax in the U.S. seeks to develop a low-cost, single-dose, oral polio vaccine using a live, safe adenovirus containing protein-encoding genes from poliovirus. If successful, this vaccine can be used to eradicate polio while eliminating the risks of vaccine-derived polio disease and poliovirus re-introduction.</p>


Kenneth Kelley of PaxVax in the U.S. seeks to develop a low-cost, single-dose, oral polio vaccine using a live, safe adenovirus containing protein-encoding genes from poliovirus. If successful, this vaccine can be used to eradicate polio while eliminating the risks of vaccine-derived polio disease and poliovirus re-introduction.

Low Cost, SIngle Dose, Oral, Live Ad4-based VP Polio Vaccine

Great ideas come from everywhere.

Sign up for email updates of the latest grant opportunities and awards.

View the Grand Challenges partnership network

.css-1nxq281{overflow:hidden;display:inline-block;}.css-1nxq281 span{display:inline-block;}Great ideas come from everywhere.

Sign up for email updates of the latest grant opportunities and awards.

View the Grand Challenges partnership network

Great ideas come from everywhere.